A Review on N-nitrosamine Impurity

IF 0.7 4区 医学 Q4 PHARMACOLOGY & PHARMACY Current Pharmaceutical Analysis Pub Date : 2024-02-04 DOI:10.2174/0115734129271377231222100236
Debangana Pal, Babu B.
{"title":"A Review on N-nitrosamine Impurity","authors":"Debangana Pal, Babu B.","doi":"10.2174/0115734129271377231222100236","DOIUrl":null,"url":null,"abstract":": Nitrosamines are a category of substances that have a nitroso group linked to an amino group in their molecular structure. They are a category of carcinogens developed as a by-product of drug synthesis and also constituted in the presence of sodium nitrite or nitric acid and secondary amines (like dimethyl amines and diethyl amine) that must be monitored in drug production. In mid-June 2018, the Food and Drug Administration and the European Medicines Agency became aware of the existence of an impurity called N-nitrosamine in some frequently used medications, such as those for blood pressure, antacids, and diabetes. N-nitrosamines are of major concern because the ICH M7 (R1)2 guideline categorizes them as Class 1 impurities or mutagenic carcinogens, and the International Agency for Cancer Research categorizes them as potential carcinogens. The existence of N-nitrosamines in pharmaceutical drugs must be minimized to the greatest extent possible and must be at or below the threshold based on ICH M7(R1)2 fundamentals for materials in the \"cohort of concern\" described in this guideline and measured based on lifetime constant exposure.","PeriodicalId":10889,"journal":{"name":"Current Pharmaceutical Analysis","volume":"8 1","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2024-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmaceutical Analysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115734129271377231222100236","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

: Nitrosamines are a category of substances that have a nitroso group linked to an amino group in their molecular structure. They are a category of carcinogens developed as a by-product of drug synthesis and also constituted in the presence of sodium nitrite or nitric acid and secondary amines (like dimethyl amines and diethyl amine) that must be monitored in drug production. In mid-June 2018, the Food and Drug Administration and the European Medicines Agency became aware of the existence of an impurity called N-nitrosamine in some frequently used medications, such as those for blood pressure, antacids, and diabetes. N-nitrosamines are of major concern because the ICH M7 (R1)2 guideline categorizes them as Class 1 impurities or mutagenic carcinogens, and the International Agency for Cancer Research categorizes them as potential carcinogens. The existence of N-nitrosamines in pharmaceutical drugs must be minimized to the greatest extent possible and must be at or below the threshold based on ICH M7(R1)2 fundamentals for materials in the "cohort of concern" described in this guideline and measured based on lifetime constant exposure.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
关于 N-亚硝胺杂质的综述
:亚硝胺是一类在分子结构中含有与氨基相连的亚硝基的物质。它们是药物合成过程中产生的一类致癌物质,也是亚硝酸钠或硝酸以及仲胺(如二甲基胺和二乙胺)存在时的致癌物质,在药物生产过程中必须受到监控。2018 年 6 月中旬,美国食品和药物管理局和欧洲药品管理局意识到,在一些常用药物(如治疗血压、抗酸剂和糖尿病的药物)中存在一种名为 N-亚硝胺的杂质。N-亚硝胺之所以备受关注,是因为 ICH M7 (R1)2 准则将其归类为 1 级杂质或诱变致癌物,而国际癌症研究机构则将其归类为潜在致癌物。必须尽最大可能减少 N-亚硝胺在药品中的存在,其含量必须达到或低于 ICH M7(R1)2 准则中所述 "关注人群 "材料的基本阈值,并根据终生持续接触进行测量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.50
自引率
0.00%
发文量
85
审稿时长
3 months
期刊介绍: Aims & Scope Current Pharmaceutical Analysis publishes expert reviews and original research articles on all the most recent advances in pharmaceutical and biomedical analysis. All aspects of the field are represented including drug analysis, analytical methodology and instrumentation. The journal is essential to all involved in pharmaceutical, biochemical and clinical analysis.
期刊最新文献
Simultaneous Estimation of Pregabalin and Duloxetine Used to Treat Nerve Pain by Stability Indicating RP-HPLC Method Using the QBD Approach Research on Compatibility of Packaging Materials of High-Risk Cephalosporin Powder Injection and Establishment of Indicator Component Evaluation Method Universally Applicable Methods for Comprehensive Risk Assessment of Elemental Impurities in Vitamin A and D Preparations An Overview of Biotechnological Drug’s Various Techniques of Downstream Process, Guideline’s And Different Chromatographic Analysis Validation of GF-AAS Method for the Determination of Aluminium Content in Human Albumin Finished Product
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1